ArticleIn vivo (Athens, Greece)
Clinical Utility of Body Weight Monitoring During Cisplatin-based Chemotherapy.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimAcute kidney injury (AKI) is one of the most frequent adverse effects induced by cisplatin (CDDP). One clinical indicator of CDDP-induced AKI is urine output, which reflects water balance; however, urine collection can expose healthcare workers to anticancer drugs. An alternative monitoring approach for CDDP-induced AKI is weight-based assessment of fluid balance. Although previous studies have evaluated the relationship between body weight change and CDDP-induced AKI, few have evaluated the amount of water ingested. Therefore, we evaluated water intake, urine output, and body weight changes in patients treated with CDDP to determine the utility of weight monitoring as an indicator of fluid balance during CDDP-based chemotherapy. PATIENTS AND
methodsWe evaluated 15 patients who received CDDP-vinorelbine as postoperative adjuvant chemotherapy for non-small cell lung cancer from March to December 2019. Patients recorded their oral fluid intake, and body weight changes were evaluated on days 2-4 relative to baseline on day 1.
resultsNo cases of CDDP-induced AKI occurred. Compared with day 1, urine output decreased on day 2 but recovered on day 3. Body weight fluctuations were highest (+3.6 kg) on day 3 and started decreasing on day 4. Serum creatinine and estimated glomerular filtration rate did not differ significantly pre- and post-chemotherapy. A positive correlation was observed between water balance and next-morning weight change (
conclusionWeight monitoring may reduce healthcare workers' exposure to anticancer agents while serving as a practical indicator of fluid balance during CDDP-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.